Organism: Homo sapiens
Gene: 38969_at
Selected probe(set): 221739_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38969_at (221739_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):2.953744
Number of Samples:6 / 6

Experimental	memory B cell study 1 (CD27high)
	CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control	memory B cell study 1 (undivided)
	CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

Relative Expression (log2-ratio):2.480648
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.348381
Number of Samples:6 / 6

Experimental	memory B cell study 1 (CD27low)
	CD27 enriched proliferating human memory B cells expressing low level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control	memory B cell study 1 (undivided)
	CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

Relative Expression (log2-ratio):2.3288136
Number of Samples:3 / 3

Experimental	glioma study 17 (glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):2.3258123
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-215)
	Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Relative Expression (log2-ratio):2.3220034
Number of Samples:2 / 3

Experimental	glioma study 17 (anaplastic astrocytoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Relative Expression (log2-ratio):2.268734
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS5)
	CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):2.1204138
Number of Samples:2 / 2

Experimental	bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control	bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

Relative Expression (log2-ratio):2.1185331
Number of Samples:3 / 3

Experimental	diclofenac study 7 (24h)
	HepG2 cells exposed to 100μM diclofenac in PBS solvent for 24 hours. ATC code:, ,
Control	vehicle (PBS) treated HepG2 cell sample
	HepG2 cells exposed to 0.5% PBS solvent for 24 hours.

Relative Expression (log2-ratio):2.0709352
Number of Samples:2 / 4

Experimental	glioma study 17 (glioblastoma; unsorted)
	Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.